ロチゴチン経皮吸収型製剤による皮膚バリア機能低下に対するヘパリン類似物質製剤の影響

抄録

We studied the effect of heparinoid pre-treatment on dermopathy caused by application of a rotigotine transdermal patch (Rotigotine). Hairless mice with intact and dry skin were used in this study. Study groups were divided into intact skin + rotigotine, dry skin + rotigotine, and dry skin + rotigotine + pre-treated heparinoid groups. The application time of rotigotine was 24 h, after which time transepidermal water loss (TEWL), stratum corneum water content and epidermal thickness in the skin were examined. TEWL in the dry skin + rotigotine group increased compared to that of the intact skin + rotigotine group. However, in the dry skin + rotigotine + pre-treated heparinoid group, TEWL was less than that of dry skin + rotigotine group animals, and epidermal thickness was increased. These results suggest that heparinoid pre-application may reduce application site failure caused by rotigotine.